BioCryst Pharmaceuticals BCRX Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost
Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's share-based goods and nonemployee services transaction, modification of terms, incremental compensation cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's share-based goods and nonemployee services transaction, modification of terms, incremental compensation cost?
- BioCryst Pharmaceuticals (BCRX) reported share-based goods and nonemployee services transaction, modification of terms, incremental compensation cost of $3.58M in Q1 2026.